IMR Press / CEOG / Volume 42 / Issue 2 / DOI: 10.12891/ceog1825.2015

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Plasma pentraxin 3 levels in preeclamptic patients
Show Less
1 Department of Obstetrics and Gynecology, Istanbul Medeniyet University Goztepe Education and Research Hospital, Istanbul
2 Department of Biochemistry, Istanbul Medeniyet University Goztepe Education and Research Hospital, Istanbul (Turkey)
Clin. Exp. Obstet. Gynecol. 2015, 42(2), 220–223; https://doi.org/10.12891/ceog1825.2015
Published: 10 April 2015
Abstract

The authors evaluated plasma pentraxin 3 (PTX 3) levels in preeclamptic patients and determined the relationship between albuminuria and plasma PTX 3 levels. During a period of one year, 29 patients with severe or mild preeclampsia and 49 healthy pregnant women were included in the cross-sectional study. The two groups were compared each other with PTX 3 levels. The relationship between PTX 3 levels and urea, creatinine, AST, ALT, CRP, LDH, platelet count, and spot urine protein/creatinine rate were evaluated. PTX 3 level was significantly high in the preeclamptic group (p < 0.05). No significant correlation was found between serum PTX 3 level and urea, creatinine, AST, ALT, CRP, LDH, platelet, and spot urine protein/creatinine rate (p > 0.05). PTX 3 is a biochemical parameter that shows endothelial dysfunction. The authors believe that PTX 3 can be a valuable parameter to predict preeclampsia according to the significantly high PTX 3 levels in preeclamptic patients.
Keywords
Pentraxin 3
Preeclampsia
Albuminuria
Share
Back to top